Literature DB >> 19201831

Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.

Dan Li1, Lu Qian, Changguo Chen, Ming Shi, Ming Yu, Meiru Hu, Lun Song, Beifen Shen, Ning Guo.   

Abstract

The presentation of peptides to T cells by MHC class II molecules is of critical importance in specific recognition to a pathogen by the immune system. The level of MHC class II directly influences T lymphocyte activation. The aim of this study was to identify the possible mechanisms of the down-regulation of MHC class II expression by Zta during EBV lytic cycle. The data in the present study demonstrated that ectopic expression of Zta can strongly inhibit the constitutive expression of MHC class II and CIITA in Raji cells. The negative effect of Zta on the CIITA promoter activity was also observed. Scrutiny of the DNA sequence of CIITA promoter III revealed the presence of two Zta-response element (ZRE) motifs that have complete homology to ZREs in the DR and left-hand side duplicated sequence promoters of EBV. By chromatin immunoprecipitation assays, the binding of Zta to the ZRE(221) in the CIITA promoter was verified. Site-directed mutagenesis of three conserved nucleotides of the ZRE(221) substantially disrupted Zta-mediated inhibition of the CIITA promoter activity. Oligonucleotide pull-down assay showed that mutation of the ZRE(221) dramatically abolished Zta binding. Analysis of the Zta mutant lacking DNA binding domain revealed that the DNA-binding activity of Zta is required for the trans repression of CIITA. The expression of HLA-DRalpha and CIITA was restored by Zta gene silencing. The data indicate that Zta may act as an inhibitor of the MHC class II pathway, suppressing CIITA transcription and thus interfering with the expression of MHC class II molecules.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201831     DOI: 10.4049/jimmunol.0802686

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Repression of CIITA by the Epstein-Barr virus transcription factor Zta is independent of its dimerization and DNA binding.

Authors:  Nicolae Balan; Kay Osborn; Alison J Sinclair
Journal:  J Gen Virol       Date:  2015-12-11       Impact factor: 3.891

2.  An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.

Authors:  Shi-Dong Ma; Xianming Yu; Janet E Mertz; Jenny E Gumperz; Erik Reinheim; Ying Zhou; Weihua Tang; William J Burlingham; Margaret L Gulley; Shannon C Kenney
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

3.  A novel bat herpesvirus encodes homologues of major histocompatibility complex classes I and II, C-type lectin, and a unique family of immune-related genes.

Authors:  Huajun Zhang; Shawn Todd; Mary Tachedjian; Jennifer A Barr; Minhua Luo; Meng Yu; Glenn A Marsh; Gary Crameri; Lin-Fa Wang
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

4.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression.

Authors:  Katharina Schmidt; Effi Wies; Frank Neipel
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

5.  The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins.

Authors:  Jillian A Bristol; Amanda R Robinson; Elizabeth A Barlow; Shannon C Kenney
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

6.  Epstein-Barr virus BGLF4 kinase downregulates NF-κB transactivation through phosphorylation of coactivator UXT.

Authors:  Ling-Shih Chang; Jiin-Tarng Wang; Shin-Lian Doong; Chung-Pei Lee; Chou-Wei Chang; Ching-Hwa Tsai; Sheng-Wen Yeh; Ching-Yueh Hsieh; Mei-Ru Chen
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

7.  Evaluation of a prediction protocol to identify potential targets of epigenetic reprogramming by the cancer associated Epstein Barr virus.

Authors:  Kirsty Flower; Elizabeth Hellen; Melanie J Newport; Susan Jones; Alison J Sinclair
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

8.  Epstein-Barr virus interferes with the amplification of IFNalpha secretion by activating suppressor of cytokine signaling 3 in primary human monocytes.

Authors:  François Michaud; François Coulombe; Eric Gaudreault; Carine Paquet-Bouchard; Marek Rola-Pleszczynski; Jean Gosselin
Journal:  PLoS One       Date:  2010-07-30       Impact factor: 3.240

9.  Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.

Authors:  Jianmin Zuo; Andrew D Hislop; Carol S Leung; Shereen Sabbah; Martin Rowe
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

Review 10.  Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity.

Authors:  Martin Rowe; Jianmin Zuo
Journal:  Microbes Infect       Date:  2010-02-01       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.